BACKGROUND: Anemia is common in HIV-infected individuals and may be associated with decreased survival. OBJECTIVE: To ascertain the impact of highly active antiretroviral therapy (HAART) on anemia and the relationship between anemia and overall survival in HIV-infected women. METHODS: A prospective multicenter study of HIV-1 infection in women. Visits occurred every 6 months, including a standardized history, physical examination, and comprehensive laboratory evaluation. The setting was a university-affiliated clinic at 6 sites in the United States. Participants were 2056 HIV-infected women from the Women's Interagency HIV Study (WIHS). The outcome measure was anemia, defined as hemoglobin (Hb) <12 g/dL. Survival analysis was based on overall mortality during the follow-up period. RESULTS: Among HIV-infected women who were not anemic at baseline, 47% became anemic by 3.5 years of follow-up. On multivariate analysis, the use of HAART was associated with resolution of anemia even when used for only 6 months (odds ratio [OR] = 1.45; P < 0.05). In the multivariate model, a CD4 cell count <200 cells/microL (OR = 0.56; P < 0.001); HIV-1 RNA level > or =50,000 copies/mL (OR = 0.65; P < 0.001), and mean corpuscular volume (MCV) value <80 fL (OR = 0.40; P < 0.001) were also associated with an inability to correct anemia. Similarly, use of HAART for 12 months or more was associated with a protective effect against development of anemia (OR = 0.71; P < 0.001). Among HIV-infected women, anemia was independently associated with decreased survival (hazard ratio [HR] = 2.58; P < 0.001). Other factors associated with decreased survival included a CD4 cell count <200 cells/microL (HR = 5.83; P < 0.001), HIV-1 RNA level > or = 50,000 copies/mL (HR = 2.12; P < 0.001), and clinical diagnosis of AIDS (HR = 2.83; P < 0.001). CONCLUSIONS: Anemia is an independent risk factor for decreased survival among HIV-infected women. HAART therapy for as little as 6 months is associated with resolution of anemia.
BACKGROUND:Anemia is common in HIV-infected individuals and may be associated with decreased survival. OBJECTIVE: To ascertain the impact of highly active antiretroviral therapy (HAART) on anemia and the relationship between anemia and overall survival in HIV-infectedwomen. METHODS: A prospective multicenter study of HIV-1 infection in women. Visits occurred every 6 months, including a standardized history, physical examination, and comprehensive laboratory evaluation. The setting was a university-affiliated clinic at 6 sites in the United States. Participants were 2056 HIV-infectedwomen from the Women's Interagency HIV Study (WIHS). The outcome measure was anemia, defined as hemoglobin (Hb) <12 g/dL. Survival analysis was based on overall mortality during the follow-up period. RESULTS: Among HIV-infectedwomen who were not anemic at baseline, 47% became anemic by 3.5 years of follow-up. On multivariate analysis, the use of HAART was associated with resolution of anemia even when used for only 6 months (odds ratio [OR] = 1.45; P < 0.05). In the multivariate model, a CD4 cell count <200 cells/microL (OR = 0.56; P < 0.001); HIV-1 RNA level > or =50,000 copies/mL (OR = 0.65; P < 0.001), and mean corpuscular volume (MCV) value <80 fL (OR = 0.40; P < 0.001) were also associated with an inability to correct anemia. Similarly, use of HAART for 12 months or more was associated with a protective effect against development of anemia (OR = 0.71; P < 0.001). Among HIV-infectedwomen, anemia was independently associated with decreased survival (hazard ratio [HR] = 2.58; P < 0.001). Other factors associated with decreased survival included a CD4 cell count <200 cells/microL (HR = 5.83; P < 0.001), HIV-1 RNA level > or = 50,000 copies/mL (HR = 2.12; P < 0.001), and clinical diagnosis of AIDS (HR = 2.83; P < 0.001). CONCLUSIONS:Anemia is an independent risk factor for decreased survival among HIV-infectedwomen. HAART therapy for as little as 6 months is associated with resolution of anemia.
Authors: Elizabeth M Widen; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Valerie L Flax; Athena P Kourtis; Sascha R Ellington; Zebrone Kacheche; Gerald Tegha; Denise J Jamieson; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Mark S Sulkowski; Craig Innes; Chloe L Thio; Richard E Chaisson; Gavin J Churchyard; Alison D Grant Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Valerie L Flax; Linda S Adair; Lindsay H Allen; Setarah Shahab-Ferdows; Daniela Hampel; Charles S Chasela; Gerald Tegha; Eric J Daza; Amanda Corbett; Nicole L Davis; Deborah Kamwendo; Athena P Kourtis; Charles M van der Horst; Denise J Jamieson; Margaret E Bentley Journal: J Nutr Date: 2015-07-08 Impact factor: 4.798
Authors: Paula E Brentlinger; Wilson P Silva; Sten H Vermund; Emilio Valverde; Manuel Buene; Troy D Moon Journal: AIDS Res Hum Retroviruses Date: 2015-08-19 Impact factor: 2.205
Authors: Macarthur Charles; Francine Noel; Paul Leger; Patrice Severe; Cynthia Riviere; Carole Anne Beauharnais; Erica Miller; John Rutledge; Heejung Bang; Wesley Shealey; Richard T D'Aquila; Roy M Gulick; Warren D Johnson; Peter F Wright; Jean William Pape; Daniel W Fitzgerald Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408
Authors: L Tugume; B M Morawski; M Abassi; N C Bahr; R Kiggundu; H W Nabeta; K H Hullsiek; K Taseera; A K Musubire; C Schutz; C Muzoora; D A Williams; M A Rolfes; G Meintjes; J Rhein; D B Meya; D R Boulware Journal: HIV Med Date: 2016-04-28 Impact factor: 3.180